Figure 2.
SM disease burden biomarkers before and after care standardization. BST (A) and KIT p.D816V VAF (B) distributions on continuous scatter plots comparing SM cases diagnosed before 1 July 2021 to those diagnosed after 1 July 2021. In panels A and B, blue dots correspond to SM cases diagnosed by 1 July 2021, and purple dots correspond to SM cases diagnosed after 1 July 2021. In panel B, red dots represent SM cases diagnosed by 1 July 2021 where KIT p.D816V VAF values were tested after 1 July 2021. Each patient’s highest lifetime KIT p.D816V VAF value of either PB or BM aspirate was used in panel B. PB and BM aspirate were also analyzed separately (see supplemental Figure 2). Mann-Whitney test was used (P value) to compare means of the 2 groups.

SM disease burden biomarkers before and after care standardization. BST (A) and KIT p.D816V VAF (B) distributions on continuous scatter plots comparing SM cases diagnosed before 1 July 2021 to those diagnosed after 1 July 2021. In panels A and B, blue dots correspond to SM cases diagnosed by 1 July 2021, and purple dots correspond to SM cases diagnosed after 1 July 2021. In panel B, red dots represent SM cases diagnosed by 1 July 2021 where KIT p.D816V VAF values were tested after 1 July 2021. Each patient’s highest lifetime KIT p.D816V VAF value of either PB or BM aspirate was used in panel B. PB and BM aspirate were also analyzed separately (see supplemental Figure 2). Mann-Whitney test was used (P value) to compare means of the 2 groups.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal